Targeting FLT3 to treat leukemia
Introduction: Approximately 23% of acute myeloid leukemia (AML) patients younger than 60 years of age carry a mutation in the transmembrane domain of the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/internal tandem duplications [ITD]). In normal karyotype AML, the presence of a FLT3/ITD mutation is...
-д хадгалсан:
| Үндсэн зохиолчид: | , |
|---|---|
| Формат: | Revisão |
| Хэл сонгох: | англи |
| Хэвлэсэн: |
2014
|
| Онлайн хандалт: | https://doi.org/10.1517/14728222.2014.960843 |
| Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|